S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH
|
|
|
- Lillian Powers
- 6 years ago
- Views:
Transcription
1 :30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome to the Symposium S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH 10:45-12:15 Standards in NSCLC in 2018 Sala B Moderation: M. Garassino, S. Rauh ; Milan, IT, Esch Sur Alzette, LU 10:45-11:05 Standards of care in locally advanced, unresectable NSCLC M. Garassino, Milan, IT 11:05-11:10 Case presentation and discussion: Locally advanced unresectable NSCLC - immuno following radio-chemo 11:10-11:25 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:25-11:30 Case presentation and discussion: Adjuvant treatment oncogene-addicted NSCLC anti EGFR / same for ALK, Ros, etc. 11:30-11:45 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 11:45-11:50 Case presentation and discussion: Metastatic oncogene addicted, PD-L1 post: treatment schedule? 11:50-12:05 Discussion M. Garassino 1, S. Rauh 2 ; 1 Milan, IT, 2 Esch Sur Alzette, LU 12:05-12:15 Conclusion and future outlook M. Garassino, Milan, IT 12:15-13:15 Lunch Sala B
2 13:15-13:45 Keynote lecture Sala B Moderation: 13:15-13:45 Immunotherapy in 2018: Hope, hype or breakthrough: An overview of use and benefit in current knowledge 13:45-15:15 Standards in melanoma in 2018 Sala B Moderation: R. Curca, O. Michielin ; Alba Iulia, RO, Lausanne, CH 13:45-13:50 Introduction and overview of the most relevant, practice-changing abstracts in 2017 R. Curca, Alba Iulia, RO 13:50-14:10 Standards of care in metastatic melanoma O. Michielin, Lausanne, CH 14:10-14:20 Case presentation: BRAF WT patient R. Curca, Alba Iulia, RO 14:20-14:40 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 14:40-14:50 Case presentation: BRAF mutant patient R. Curca, Alba Iulia, RO 14:50-15:10 Discussion R. Curca 1, O. Michielin 2 ; 1 Alba Iulia, RO, 2 Lausanne, CH 15:10-15:15 Conclusions and future outlook O. Michielin, Lausanne, CH 15:15-15:45 Coffee break Sala B
3 15:45-17:30 Standards in colorectal cancer in 2018 Sala B Moderation: M. Karamouzis, D. Arnold ; Kolonaki, Athens/GR, Hamburg, DE 15:45-15:55 Introduction M. Karamouzis 1, D. Arnold 2 ; 1 Kolonaki, GR, 2 Lisbon, PT 15:55-16:20 Are we ready to change the duration of adjuvant chemotherapy in 2018? Adjuvant treatment of rectal cancer what s new in 2018? D. Arnold, Hamburg, DE 16:20-16:45 Metastatic colorectal cancer - what s new in 2018? M. Karamouzis, Kolonaki, GR 16:45-16:50 Case presentation: Early stage disease M. Karamouzis, Kolonaki, GR 16:50-17:05 Discussion D. Arnold, Hamburg, DE 17:05-17:10 Case presentation: Metastatic stage disease D. Arnold, Lisbon, PT 17:10-17:25 Discussion M. Karamouzis, Kolonaki, Athens/GR 17:25-17:30 Conclusions and future outlook D. Arnold 1, M. Karamouzis 2 ; 1 Hamburg, DE, 2 Kolonaki, Athens/GR
4 17:30-19:00 Standards in non-hodgkin's lymphoma in 2018 Sala B Moderation: R. Eckert, M. Ghielmini ; Esslingen, DE, Bellinzona, CH 17:30-17:35 Introduction 17:35-17:55 Standards of care in NHL M. Ghielmini, Bellinzona, CH 17:55-18:05 Case presentation 1 18:05-18:25 Discussion R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:25-18:35 Case presentation 2 18:35-18:55 Discussion R. Eckert 1, M. Ghielmini 2 ; 1 Esslingen, DE, 2 Bellinzona, CH 18:55-19:00 Conclusions and future outlook M. Ghielmini, Bellinzona, CH
5 09:00-10:30 Standards in locally advanced, non-metastatic upper GI cancers (Gastroesophageal) in 2018 Sala B Moderation: G. Lakatos, M. Ducreux ; Budapest, HU, Villejuif, CEDEX/FR 09:00-09:05 Introduction G. Lakatos, Budapest, HU 09:05-09:25 Standards of care in upper GI cancers M. Ducreux, Villejuif, CEDEX/FR 09:25-09:35 Case presentation: Locally advanced oesophageal cancer G. Lakatos, Budapest, HU 09:35-09:55 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 09:55-10:05 Case presentation: Locally advanced gastric cancer G. Lakatos, Budapest, HU 10:05-10:25 Discussion G. Lakatos 1, M. Ducreux 2 ; 1 Budapest, HU, 2 Villejuif, CEDEX/FR 10:25-10:30 Conclusions and future outlook M. Ducreux, Villejuif, CEDEX/FR 10:30-11:00 Coffee break Sala B
6 11:00-12:30 Standards in metastatic prostate cancer in 2018 Sala B Moderation: A. Froebe, M. De Santis ; Zagreb, HR, Berlin, DE 11:00-11:05 Introduction A. Froebe, Zagreb, HR 11:05-11:25 Standards of care in metastatic prostate cancer M. De Santis, Coventry, GB 11:25-11:35 Case presentation: Metastatic prostate cancer upon initial diagnosis: CHAARTED, etc. A. Froebe, Zagreb, HR 11:35-11:55 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Coventry, GB 11:55-12:05 Case presentation: CRPC incl. therapeutic use of isotopes in metastatic prostate cancer A. Froebe, Zagreb, HR 12:05-12:25 Discussion A. Froebe 1, M. De Santis 2 ; 1 Zagreb, HR, 2 Coventry, GB 12:25-12:30 Conclusions and future outlook M. De Santis, Berlin, DE 12:30-13:30 Lunch Sala B 13:30-14:00 Keynote lecture: San Salvatore award lecture Sala B Moderation: R.A. Stahel, S. Rauh ; Zürich, CH, Esch Sur Alzette, LU 13:30-14:00 To be announced
7 14:00-15:30 Standards in bladder and kidney metastatic cancers in 2018 Sala B Moderation: J. Molitor, Y. Vano; Paris, FR 14:00-14:05 Introduction J. Molitor, Paris, FR 14:05-14:25 Standards of care in bladder and kidney cancer Y. Vano, Paris, FR 14:25-14:35 Case presentation: Immunotherapy in kidney cancer: When? J. Molitor, Paris, FR 14:35-14:55 Discussion J. Molitor, Y. Vano; Paris, FR 14:55-15:05 Case presentation: Second-line treatment for bladder cancer J. Molitor, Paris, FR 15:05-15:25 Discussion Y. Vano, J. Molitor; Paris, FR 15:25-15:30 Conclusions and future outlook Y. Vano, Paris, FR 15:30-16:00 Coffee break Sala B
8 16:00-17:30 Standards in breast cancer in 2018 Sala B Moderation: S. Braga, A. Gennari ; Lisbon, PT, Genova, IT 16:00-16:20 Standards of care in neo-adjuvant /adjuvant breast cancer A. Gennari, Genova, IT 16:20-16:30 Case presentations: An (elderly) patient with HER2 neo adjuvant - adjuvant treatment S. Braga, Lisbon, PT 16:30-16:45 Discussion S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 16:45-17:05 Standards of care in metastatic breast cancer, including CDK4 inhibitors and impact on treatment A. Gennari, Genova, IT 17:05-17:15 Case presentation: Who benefits from CDK4 inhibitors? Toxicity issues S. Braga, Lisbon, PT 17:15-17:30 Discussion and future outlook S. Braga 1, A. Gennari 2 ; 1 Lisbon, PT, 2 Genova, IT 17:30-18:00 Workshop: Managing survivorship care Sala B Moderation: 17:30-17:50 ESMO guidelines and survivorship guide 17:50-18:00 Interactive discussion 18:00-19:00 Networking Foyer
9 09:00-10:30 Standards in multiple myeloma in 2018 Sala B Moderation: R. Eckert, J. Harousseau ; Esslingen, DE, Nantes, CEDEX 1/FR 09:00-09:05 Introduction (including overview of the 4 most relevant, practice-changing abstracts in 2017) 09:05-09:35 Standards of care in multiple myeloma J. Harousseau, Nantes, CEDEX 1/FR 09:35-09:45 Case presentation 1 09:45-10:00 Discussion R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, FR 10:00-10:10 Case presentation 2 10:10-10:25 Discussion R. Eckert 1, J. Harousseau 2 ; 1 Esslingen, DE, 2 Nantes, FR 10:25-10:30 Conclusions and future outlook J. Harousseau, Nantes, FR 10:30-11:00 Coffee break Sala B
10 11:00-12:00 Workshop: Management of immunotherapy related toxicity Sala B Moderation: S. Rauh, J. Haanen ; Esch Sur Alzette, LU, Amsterdam, NL 11:00-11:03 Case: Skin toxicity 11:03-11:12 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:12-11:15 Management proposal 11:15-11:18 Case: Hepatotoxicity 11:18-11:27 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:27-11:30 Management proposal 11:30-11:33 Case: Lung toxicity 11:33-11:42 Discussion J. Haanen 1, S. Rauh 2 ; 1 Amsterdam, NL, 2 Esch Sur Alzette, LU 11:42-11:45 Management proposal 11:45-11:48 Case: Endocrine or other 11:48-11:57 Discussion 11:57-12:00 Management proposal
11 12:00-12:30 Workshop: Allergic reactions to chemotherapy- Management including desensibilisation Sala B Moderation: H. van Halteren, Vlissingen, NL 12:00-12:20 The allergologist s contribution to chemo allergies H. van Halteren, Vlissingen, NL 12:20-12:30 Discussion 12:30-12:45 Closing remarks Sala B Moderation: 12:30-12:45 Closing remarks S. Rauh, Esch, LU 12:45-13:15 Lunch Foyer
S. Rauh 1, J. Douillard 2 ; 1 Esch Sur Alzette, LU, 2 Lugano - Viganello, CEDEX/CH
27.04.2018 10:30-10:45 Opening and welcome Sala B Moderation: S. Rauh, J. Douillard ; Esch Sur Alzette, LU, Lugano - Viganello, CEDEX/CH 10:30-10:45 Welcome and introduction S. Rauh 1, J. Douillard 2 ;
Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT. Moderation: S. Rauh, Esch, LU
03-03-2017 13:30-13:45 Opening and welcome Auditorium Moderation: S. Rauh, D. Arnold ; Esch, LU, Lisbon, PT 13:30-13:45 Welcome to the Conference 13:45-14:15 Keynote lecture Auditorium Moderation: 13:45-14:15
Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES
08-04-2017 12:45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs 1 2 1 2 Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15
Berlin. Title: Industry Satellite Symposium. Vienna. Title: Industry Satellite Symposium. Exhibition area. Title: Welcome reception
02.05.2019 12:00-13:00 Type: Industry Satellite Symposium 12:00-13:00 Type: Industry Satellite Symposium 13:00-13:30 Type: Opening session Title: Welcome reception Exhibition area 13:30-13:45 Type: Opening
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme July 2016, Valencia, Spain
ESMO-ESO Course on Medical Oncology for Medical Students Educational Programme 14-19 July 2016, Valencia, Spain Co-chairs: Andrés Cervantes, ES - Nicholas Pavlidis, GR - Susana Banerjee, UK Thursday, 14
:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves Douillard, France
ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves
PRECEPTORSHIP PROGRAMME
esmo.org PRECEPTORSHIP PROGRAMME Gastrointestinal Tumours Multidisciplinary management, standards of care and future perspectives SINGAPORE 20-22 OCTOBER 2016 Co-Chairs Jean-Yves Douillard, Switzerland
Colorectal Cancer Multidisciplinary management, standards of care and future perspectives
ESMO Preceptorship Programme Colorectal Cancer Multidisciplinary management, standards of care and future perspectives Prague, Czech Republic 6-7 July 2016 CO-CHAIRS: Andrés Cervantes, Spain Jean-Yves
Amphithéâtre Bordeaux. Amphithéâtre. C. Massard, Villejuif, CEDEX/FR. N. Rizvi, New York, NY/US
25.02.2019 08:45-09:30 Opening and welcome + Honorary award Keynote lecture 08:45-08:55 Welcome address 08:55-09:00 Presentation of the TAT 2019 Honorary Award 09:00-09:30 TAT 2018 Honorary Award Keynote
ESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
CLINICAL ONCOLOGY March 2012 Ermatingen (Lake Constance), Switzerland
MASTERCLASS ERMATINGEN 17/03/12 11 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: N. Pavlidis, GR - R.A. Stahel, CH Scientific Co-ordinators:
ICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
CLINICAL ONCOLOGY 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN May 2013 Dubrovnik, Croatia. Chair: R. Popescu, CH/RO Co-chair: S.
MASTERCLASS 3 RD BALKAN AND EASTERN EUROPEAN MASTERCLASS IN CLINICAL ONCOLOGY 8-12 May 2013 Dubrovnik, Croatia Chair: Co-chair: S. Beslija, BA Aims and objectives This clinically oriented residential educational
Gastric Cancer Co-Chairs Speakers LEARNING OBJECTIVES
ESMO Preceptorship Programme Gastric Cancer Multidisciplinary management, standards of care, therapeutic targets and future perspectives 10-11 June 2016, Prague, Czech Republic Co-Chairs Andres Cervantes
ONCOLOGY NURSING 9 TH ESO-EONS MASTERCLASS IN March 2016 Ermatingen (Lake Constance) Switzerland #16MON
MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 9 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 12-17 March 2016 Ermatingen
10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING march 2017 nauen ot Groß Behnitz (Berlin area), Germany. masterclass
10 th ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 25-30 march 2017 nauen ot Groß Behnitz (Berlin area), Germany Chairs: B. Grube, DK - C. Lacerda, PT Coordinator: E. van Muilekom, NL Advisor: masterclass
ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY November 2018 Yerevan, Armenia MASTERCLASS
ESO-ASCO MASTERCLASS IN CLINICAL ONCOLOGY 10-13 November 2018 Yerevan, Armenia Chairs: G. Curigliano, IT F. Peccatori, IT Host Chair: G. Tamamyan, AM Held in collaboration with MASTERCLASS AIMS AND OBJECTIVES
New Developments in Cancer Treatment. Ian Rabinowitz MD
New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis
High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)
Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific
W. Eberhardt, Essen, DE. M. Pless, Winterthur, CH. D. De Ruysscher, Maastricht, NL. Moderation: R. Rami-Porta, Terrassa, Barcelona/ES
10.04.2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
ROOM: CONRAD + ARNOLD. ROOM: CONRAD + ARNOLD Focus on ESO, ESMO and EONS Nicholas Pavlidis, Rolf Stahel,
17h ESO-ESMO Masterclass in Clinical Oncology 24-29 March 2018, Berlin, Germany In collaboration with the Flims Alumni Club Chair: Nicholas Pavlidis, GR and Rolf A. Stahel, CH Scientific Advisors: R. Popescu,
II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Are the ESMO guidelines adapted to the elderly? D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Clinical practice guidelines Definition > Systemically developed statements
The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb
The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March
Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
Programme - Friday, 7 September
Programme - 15th Meeting of the EAU Robotic Urology Section Room: Auditorium Actual programme might be subject to change due to live surgery Live broadcasts from Institut Paoli-Calmettes and Hôpital Nord,
MEDICAL ONCOLOGY ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN. 27 June - 2 July 2014 Brdo, Slovenia. Chairs: T. Cufer, SI R.
Flyer MMO_(4 Mar)_screen 04.04.2014 09:33 Pagina 3 MASTERCLASS ESO-ESMO EASTERN EUROPE AND BALKAN REGION MASTERCLASS IN MEDICAL ONCOLOGY 27 June - 2 July 2014 Brdo, Slovenia Chairs: R. Herrmann, CH This
6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
ESOU programme Prostate cancer screening: Why screening programme should not be adopted in > 65 A. Heidenreich, Aachen (DE)
Friday, 17 January 08.30-08.40 Welcome M. Babjuk, Prague (CZ) M. Brausi, Modena (IT) 08.40-09.00 Opening address ESOU programme 09.00-11.00 Prostate cancer I: Screening, diagnosis, staging and treatment
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
Cancer Prevention & Control in Adolescent & Young Adult Survivors
+ Cancer Prevention & Control in Adolescent & Young Adult Survivors NCPF Workshop July 15-16, 2013 Patricia A. Ganz, MD UCLA Schools of Medicine & Public Health Jonsson Comprehensive Cancer Center + Overview
Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07/15 Last Review Date: 04/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
ESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
October 6-7, 2017 Marseille, France
Program Chairs M. Ahluwalia (US) E. Le Rhun (FR) P. Métellus (FR) M. Weller (CH) Scientific Committee M. Ahluwalia (US) Z. Ram (IL) F. Dhermain (FR) R. Soffietti (IT) E. Le Rhun (FR) M. Weller (CH) P.
4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2018 Mexico City, Mexico LATIN-AMERICA PROGRAMME
4 TH ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 18-22 April 2018 Mexico City, Mexico Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.
SUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
Keytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
CANCER BIOLOGY FOR CLINICIANS
www.esmo.org/events CANCER BIOLOGY FOR CLINICIANS Symposium Nice, France 26-27 November 2010 Program Book 1 Organization and contacts Organization, Program, Registration ESMO Head Office c/o ESMO Congress
Progress in Tumor Research
Immuno-Oncology Progress in Tumor Research Vol. 42 Series Editors Rolf A. Stahel Zurich Solange Peters Lausanne Immuno-Oncology Volume Editors Olivier Michielin Lausanne George Coukos Lausanne 8 figures,
PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH Dear Colleagues, The European School of Oncology is
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
Merck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
oncology For 9 th eso-esmo course on July 2012 ioannina, Greece
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK
Keytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
Room A. Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH. Room A. Title: Opening and welcome.
13.12.2018 11:15-12:45 Type: Educational session Title: Introduction to immunotherapy in cancer Chair(s): K. Kerr, GB; P. Romero, CH 11:15-11:35 Back to the basics P. Romero, Epalinges, CH 11:35-11:55
Programme - Wednesday, 5 September
Programme - Wednesday, 5 September 15th Meeting of the EAU Robotic Urology Section Room: Auditorium Actual programme might be subject to change due to live surgery Live broadcasts from Institut Paoli-Calmettes
ONCOLOGY NURSING 6 TH ESO-EONS MASTERCLASS IN March 2013 Ermatingen (Lake Constance) Switzerland MASTERCLASS
MASTERCLASS Photo: Turm by Stephan Balkenhol - A Sculpture for Wolfsberg Photographer: Ralph Feiner, Architekturfotografie, Malans 6 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 16-21 March 2013 Ermatingen
ASKLEPIOS Course SYMPOSIUM ON IMAGING HALLMARKS OF CANCER. Education in partnership. October 18 19, 2018 Lisbon/Portugal. myesr.
ON IMAGING HALLMARKS OF CANCER Education in partnership Course information The Symposium is designed for scientist, radiologists, nuclear medicine physicians and other experts in cancer imaging interested
Keytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors
First SAMO Workshop on Multidisciplinary Approaches to Gastrointestinal Tumors 25 th and 26 th April 2008 Hotel Hermitage, Lucerne Continuous Education SGMO/SSMO 10 credits (category B) SRO 10 credits
Merck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
Studienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
Merck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME
3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.
Clinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
Outcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
Gastrointestinal Oncology
2 nd MD ANDERSON INTERNATIONAL MEETING IN Gastrointestinal Oncology CURRENT PRACTICE AND CONTROVERSIES in the Era of Personalized Medicine e Madrid, 13 th -15 th November, 2019 SCIENTIFIC PROGRAM Meeting
Saturday, 13 February 2016
Saturday, 13 February 2016 16.10 16.15 Opening and welcome C.R. Chapple, Sheffield (GB) 16.15 18.00 What is new in urology 1 Chairs: C. R. Chapple, Sheffield (GB) 16.15 16.35 Functional urology C. Gratzke,
First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.
MASTERCLASS 6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY Held with the support of 11-16 June 2016 Berlin, Germany Chairs: A. Eggert, DE B. Morland, UK R. Riccardi, IT INTRODUCTION ESO and SIOP-Europe
Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma
NIHR Innovation Observatory Evidence Briefing: January 2018 Pembrolizumab in combination with epacadostat for unresectable or metastatic melanoma NIHRIO (HSRIC) ID: 7812 NICE ID: 9396 LAY SUMMARY Melanoma
3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany
3. ITLT Essen 2013 Interdisciplinary Treatment of Liver Tumors April 18-20, 2013 Essen, Germany Scientific Program Thursday, 18th April 2013 HR Thursday, 18th April 08:00 Breakfast Symposia 09:00 Registration
Chair: W. Eberhardt, DE; S. Peters, CH. 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A. 13:30-13:45 Opening and Welcome Room B
13-04-2016 12:00-13:00 Industry Satellite Symposium 1 (TBC) Room A 13:30-13:45 Opening and Welcome Room B Chair: W. Eberhardt, DE; S. Peters, CH 13:45-14:15 Heine H. Hansen Award Lecture Room B 14:30-16:00
Macmillan Publications
S1 S2 S3 S3 S3 S4 S5 S6 S7 S8 S8 S9 S10 S11 S11 S12 S13 S14 S15 S17 S18 S19 Bladder Cancer: Non-Invasive, Invasive and Advanced Bone Cancer: Primary, Secondary Colon Cancer, Anal Cancer, Rectal Cancer
ONCOLOGY NURSING March 2012 Ermatingen (Lake Constance), Switzerland
MASTERCLASS ERMATINGEN 17/03/12 5 TH ESO-EONS MASTERCLASS IN ONCOLOGY NURSING 17-22 March 2012 Ermatingen (Lake Constance), Switzerland Chairs: A. Margulies, CH - S. Faithfull, UK Scientific Coordinator:
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
TUESDAY, 18th OCTOBER, 2016 / DAY -2
Legend: Keynote Educational PODC Symposium Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite Symposium SIOPe GA SIOP ABM Late
MERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
JY Douillard MD, PhD Professor of Medical Oncology
Colorectal Cancer ESMO Preceptorship Program Prague May 22-23rd 2014 Review of the ESMO Consensus Conference on metastatic colo-rectal cancer Basic strategy and groups (RASwt/mut, BRAF mut) JY Douillard
SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016
Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC 20037 October 19-21, 2016 Wednesday, October 19, 2016 7:30 8:30 AM Registration
TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)
Legend: Keynote Educational Meet the Expert (MTE) Paediatric Psycho-Oncology () Opening/Closing Award Session Free Paper Session (FPS) Session Satellite SIOPe GA SIOP ABM Late Breaker Session Networking
Immunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
SCOTTISH ONCOLOGY SUMMIT Double Tree by Hilton, Dunblane Hydro, Dunblane 1 st - 2 nd September 2017
Friday 1 st September 1300h 1400h Lunch (arrival, registration at conference foyer, coffee and sponsors exhibition) 1400h 1420h Prof Robert Jones Welcome/Announcements 1430h 1600h Parallel sessions: Lung
3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY April 2017 San Jose, Costa Rica LATIN-AMERICA PROGRAMME
3RD ESO-ESMO LATIN-AMERICAN MASTERCLASS IN CLINICAL ONCOLOGY 26-30 April 2017 San Jose, Costa Rica Chairs: A. Cervantes, ES - N. Pavlidis, GR R.A. Stahel, CH Scientific Co-ordinators: M. Aapro, CH - F.
CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
Cancer diagnosis and treatments- brief overview of the changing paradigm.
Cancer diagnosis and treatments- brief overview of the changing paradigm. Pranshu Bansal MD New Mexico Cancer Center Identifying cancer in clinic Most common cancers are lung, breast, colon, prostate and
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
Keytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
I. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
Infographic (right): ESMO 2014 record breaking Congress
ESMO 2014 Congress Scientific Meeting Report Precision Medicine in Cancer Care 26-30 September 2014 Madrid, Spain Summary The European Society for Medical Oncology (ESMO) Congress, held September 26 to
Wojciech Nowak, Rector of the Jagiellonian University Medical College, Kraków (PL)
Chairs Jakub Kenig, Jagiellonian University Medical College, Kraków (PL) Riccardo A. Audisio, Whiston Hospital, University of Liverpool, Liverpool, (UK) Tomasz Grodzicki, Jagiellonian University Medical
State of the Art Symposium
Programme th State of the Art Symposium Programme 20 th State of the Art Symposium Saturday, January 27 th, 2018 Chairpersons Session 1: Session 2: Prof. Britta Engelhardt, Bern PD Dr. Christian Kamm,
K-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
Program Schedule. Discussion 2: Is There a Role for Non-Operative Management? Case Presenter: Chris L. Hallemeier, M.D.
Mayo Clinic Gastrointestinal Cancers 2018 Current and Emerging Strategies in Multidisciplinary Care: Translating Evidence into Best Practices March 1-3, 2018 Thursday, March 1, 2018 Program Schedule 12:00
LUNG CANCER. ASCO Poster Review. Paolo Bironzo Department of Oncology University of Torino S. Luigi Gonzaga Hospital Orbassano (TO)
LUNG CANCER ASCO Poster Review Paolo Bironzo Department of Oncology University of Torino S. Luigi Gonzaga Hospital Orbassano (TO) pbironzo@unito.it Agenda Locally advanced NSCLC: ETOP-NICOLAS phase 2 trial
Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA
THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA Presented by: Bryan Rettig, MS Nebraska Dept. of Health & Human Services Division of Public Health May 31, 2017 Nebraska Cancer Registry